Comparative Efficacy of Single Pill Combinations of Azilsartan Medoxomil/Chlorthalidone and Losartan/Hydrochlorothiazide in Patients with Hypertension and Heart Failure with Preserved Ejection Fraction

Aim. To study the effects of azilsartan medoxomil/chlorthalidone (AZM/CTD) and losartan/hydrochlorothiazide (LOS/HCT) combinations for NTproBNP levels, 6-minute walk test results, hydration status along with their antihypertensive efficacy according to clinical and 24-hour blood pressure in patients...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Рациональная фармакотерапия в кардиологии
المؤلفون الرئيسيون:	Zh. D. Kobalava, A. F. Safarova, Kh. M. Gudieva, M. A. Markova, A. E. Petrosyan
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Столичная издательская компания 2022-05-01
الموضوعات:	azilsartan medoxomil chlorthalidone 24-h blood pressure monitoring central blood pressure nt-probnp 6 minute walk test biva heart failure with preserved ejection fraction fpef
الوصول للمادة أونلاين:	https://www.rpcardio.online/jour/article/view/2706

مواد مشابهة

Looking for an optimal antihypertensive combination. Focus on azilsartan medoxomil/chlorthalidone
حسب: M. D. Smirnova, وآخرون
منشور في: (2025-01-01)

Comparative analysis of antihypertensive effects of chlorthalidone and indapamide-retard in combination with azilsartan medoxomil in patients with arterial hypertension
حسب: Zh. D. Kobalava, وآخرون
منشور في: (2019-07-01)

Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
حسب: Attila Juhasz, وآخرون
منشور في: (2018-02-01)

MODERN OPPORTUNITIES FOR ANTIHYPERTENSION THERAPY: THE PLACE OF AZILSARTAN MEDOXOMIL
حسب: V. V. Skibitsky, وآخرون
منشور في: (2017-12-01)

EFFICACY OF AZILSARTAN MEDOXOMIL ON THE DAILY PROFILE OF PERIPHERAL AND CENTRAL ARTERIAL PRESSURE AND ARTERIAL STIFFNESS IN HYPERTENSIVES WITH TYPE 2 DIABETES
حسب: E. A. Troitskaya, وآخرون
منشور في: (2017-02-01)

Comparison of Cardiovascular Outcomes Between Chlorthalidone and Hydrochlorothiazide in Hypertensive Patients
حسب: Subin Lim, وآخرون
منشور في: (2025-02-01)

Efficacy and safety of azilsartan medoxomil in the treatment of hypertension: a systematic review and meta-analysis
حسب: Ling Zhu, وآخرون
منشور في: (2024-07-01)

Central Composite Design Implemented Azilsartan Medoxomil Loaded Nanoemulsion to Improve Its Aqueous Solubility and Intestinal Permeability: In Vitro and Ex Vivo Evaluation
حسب: Girish Kumar, وآخرون
منشور في: (2022-10-01)

Azilsartan medoxomil for improving insulin resistance and adipokine levels in hypertension in comparison with angiotensin-converting enzyme inhibitors
حسب: S. V. Nedogoda, وآخرون
منشور في: (2020-08-01)

Optimizing Blood Pressure Control: A Randomized Comparative Trial of Losartan/Chlorthalidone vs. Losartan/Hydrochlorothiazide
حسب: Isabel E. Rucker-Joerg, وآخرون
منشور في: (2025-04-01)

AZILSARTAN AS A POTENT ANTIHYPERTENSIVE DRUG WITH POSSIBLE PLEIOTROPIC CARDIOMETABOLIC EFFECTS: A REVIEW STUDY.
حسب: Georgiopoulos Georgios, وآخرون
منشور في: (2016-08-01)

Dipping pattern of nocturnal blood pressure in hypertensive patients treated with azilsartan
حسب: P. L. N. Kapardhi, وآخرون
منشور في: (2020-01-01)

Efficacy of azilsartan medoxomil in patients with hypertension and stable coronary artery disease in combination with type 2 diabetes
حسب: A. M. Kochergina, وآخرون
منشور في: (2023-11-01)

Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER‐Prevention Randomized Clinical Trial
حسب: Sandra Costa Fuchs, وآخرون
منشور في: (2016-12-01)

EVALUATION OF ANTIHYPERTENSIVE THERAPY WITH THE COMBINATION OF OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
حسب: Steven G. Chrysant, وآخرون
منشور في: (2011-06-01)

Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double‐blind, active‐controlled, multicenter phase 3 trial
حسب: Eun Joo Cho, وآخرون
منشور في: (2023-09-01)

Chlorthalidone, not hydrochlorothiazide, is the right diuretic for comparison
حسب: Ravi Tejraj Mehta, وآخرون
منشور في: (2018-03-01)

The Antihypertensive Efficacy of Chlorthalidone and Telmisartan in Indian Hypertensive Patients who were Uncontrolled with Hydrochlorothiazide and Telmisartan Combination-A Prospective and an Open Label Study
حسب: Suresh V Sagarad, وآخرون
منشور في: (2014-04-01)

Thiazide‐Associated Hyponatremia: A Retrospective Cohort Study Comparing Hydrochlorothiazide Versus Indapamide Versus Chlorthalidone
حسب: Josef Klhůfek, وآخرون
منشور في: (2025-05-01)

Efficacy and safety of olmesartan medoxomil‐amlodipine besylate tablet in Chinese patients with essential hypertension: A prospective, single‐arm, multi‐center, real‐world study
حسب: Zhaoqiang Cui, وآخرون
منشور في: (2024-01-01)

Quality Assessment of medication containing chlorthalidone
حسب: Juliana de Oliveira Alves, وآخرون
منشور في: (2017-07-01)

The effect of chlorthalidone on cardiovascular and renal disease: A systematic review
حسب: Suryono Suryono, وآخرون
منشور في: (2025-01-01)

Chlorthalidone induced acute severe prolonged life-threatening hyponatremia
حسب: Naveen Garg, وآخرون
منشور في: (2018-01-01)

ANTIHYPERTENSIVE EFFICACY OF OLMESARTAN MEDOXOMIL, A NEW ANGIOTENSIN II RECEPTOR ANTAGONIST, AS ASSESSED BY AMBULATORY BLOOD PRESSURE MEASUREMENTS
حسب: J. M. Neutel, وآخرون
منشور في: (2011-04-01)

Chlorthalidone versus hydrochlorothiazide for preventing cardiovascular disease in hypertension: Is the case closed?
حسب: Anastasios Kollias, وآخرون
منشور في: (2023-09-01)

Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process
حسب: Mac Arturo Murillo-Fernández, وآخرون
منشور في: (2022-02-01)

COMBINATION OF AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE: IS IT POSSIBLE TO FIGHT SYSTEMIC HYPERTENSION AND OBESITY TOGETHER?
حسب: Yu. A. Vasyuk, وآخرون
منشور في: (2017-10-01)

Monotherapy treatment with chlorthalidone or amlodipine in the systolic blood pressure intervention trial (SPRINT)
حسب: Deep Vakil, وآخرون
منشور في: (2021-07-01)

Sartans in the treatment of arterial hypertension: focus on telmisartan and azilsartan. A review
حسب: Vadim D. Zakiev, وآخرون
منشور في: (2023-11-01)

Influence of asilsartan medoxomile on arterial hypertension variability in patients with arterial hypertension and chronic obstructive pulmonary disease
حسب: N. Yu. Grigorieva, وآخرون
منشور في: (2021-06-01)

Possible combined effect of perindopril and Azilsartan in an experimental model of dementia in rats
حسب: Yahya M. Alzahrani, وآخرون
منشور في: (2020-05-01)

Clinical effectiveness and safety of amlodipine/losartan‐based single‐pill combination therapy in patients with hypertension: Findings from real‐world, multicenter observational databases
حسب: Jieun Lee, وآخرون
منشور في: (2021-11-01)

Circulating microRNA Biomarkers of Thiazide Response in Hypertension
حسب: Lakshmi Manasa S. Chekka, وآخرون
منشور في: (2024-02-01)

UPLC–MS/MS for the determination of azilsartan in beagle dog plasma and its application in a pharmacokinetics study
حسب: Cheng Gong, وآخرون
منشور في: (2015-06-01)

Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial
حسب: Takaichi Suehiro, وآخرون
منشور في: (2021-03-01)

Tailoring Chlorthalidone Aqueous Solubility by Cocrystallization: Stability and Dissolution Behavior of a Novel Chlorthalidone-Caffeine Cocrystal
حسب: Christian Rodríguez-Ruiz, وآخرون
منشور في: (2022-01-01)

Olmesartan medoxomil-loaded mixed micelles: Preparation, characterization and in-vitro evaluation
حسب: Mohamed A. El-Gendy, وآخرون
منشور في: (2017-12-01)

Optimization, characterization and in vitro/vivo evaluation of azilsartan nanocrystals
حسب: Jingjing Ma, وآخرون
منشور في: (2017-07-01)

Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs
حسب: S. V. Nedogoda, وآخرون
منشور في: (2019-02-01)

Coadministration of Cardiomagnyl with Edarbi/Edarbi Clo in comparison with enteric-coated acetylsalicylic acid and renin-angiotensin-aldosterone system blockers in patients with hypertension and atherosclerotic cardiovascular diseases in the Russian Federation. Results of the CARAT study
حسب: F. T. Ageev, وآخرون
منشور في: (2025-07-01)